Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022
TORONTO, ONTARIO May 19, 2022 - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from May 24 – 26, 2022 in Miami, Florida. Braxia Scientific CEO Dr. Roger McIntyre will present an overview of the Company's business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression and expanding the clinical research infrastructure required to execute on the Company's growing pipeline of registered clinical trials alongside third-party sponsors. Braxia's trials include Canada's first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and is expected to report preliminary results in the coming weeks. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright...
KETAMINE AND ESKETAMINE TREATMENT GUIDANCE
AMERICAN JOURNAL OF PSYCHIATRY PUBLISHES INTERNATIONAL KETAMINE AND ESKETAMINE TREATMENT GUIDANCE LED BY BRAXIA SCIENTIFIC CEO DR. ROGER MCINTYRE International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of...